Menu Back toSession 9: Hot Topics

DIA/FDA Oligonucleotide-Based Therapeutics Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!

Session 9: Hot Topics

Session Chair(s)

Arthur A. Levin, PhD

Arthur A. Levin, PhD

  • CSO
  • Avidity Biosciences , United States
Emily  Place, PhD, MPH

Emily Place, PhD, MPH

  • Senior Consultant
  • Biologics Consulting, United States
Attendees at this session will hear about novel technologies that are bridging the gap between early research and clinical development. Each is an area that holds the promise of creating a new platform for oligonucleotide therapeutics. Featured in this session are:
  • A novel delivery platform using a conjugate approach
  • Circular RNAs as potential therapeutics
  • A novel and personalized aptamer technology in oncology
Learning Objective : At the conclusion of this session, participants should be able to:
  • Discuss insights into the promise of these technologies and how these technologies have the potential for broad applications
  • Explore where the oligonucleotide therapeutics field will advance in the future


Irit  Carmi-Levy, PhD

AUMMUNE Therapy Driven by Effect

Irit Carmi-Levy, PhD

  • Chief Scientific Officer and Vice President R&D
  • Aummune, Israel
Chris  Duke, MBA, MPH

A Novel Antibody Platform for Nucleic Acid Delivery with Broad Therapeutic Potential

Chris Duke, MBA, MPH

  • Cheif Operating Officer
  • Gennao Bio, United States
Robert  Mabry, PhD

The Therapeutic Potential of oRNA

Robert Mabry, PhD

  • Chief Scientific Officer
  • Orna Therapeutics, Inc. , United States